文献速递外周动脉疾病

慢性肢体威胁性缺血下肢血运重建后双联抗血小板治疗的影响

Impact of dual antiplatelet therapy after lower extremity revascularization for chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2021-05-20

本研究基于Vascular Quality Initiative注册数据,纳入2003至2018年因慢性肢体威胁性缺血(CLTI)行择期下肢血运重建并出院时接受单联(MAPT)或双联抗血小板治疗(DAPT)的患者。共50,890例,其中33,781例接受腔内治疗(EVT),17,109例接受开放手术(OS)。结论:DAPT与改善无截肢生存率和总生存率相关,且与EVT后靶病变再干预减少相关,但未显著改善大截肢。

要点

  • CLTI下肢血运重建后出院时DAPT与改善无截肢生存率和总生存率相关。
  • DAPT未显著降低EVT或OS后大截肢风险。

核心结论

  • 在CLTI患者中,出院时DAPT对EVT和OS后的无截肢生存率和总生存率有积极影响,并减少EVT后靶病变再干预。
  • DAPT与EVT或OS后大截肢的改善无显著关联。

研究设计与样本

  • 回顾性队列研究,使用Vascular Quality Initiative注册数据,纳入2003至2018年因CLTI行择期下肢血运重建并出院时接受MAPT或DAPT的患者。
  • 共50,890例患者,其中33,781例接受EVT,17,109例接受OS。

主要发现

  • Kaplan-Meier分析显示,出院时MAPT相比DAPT,EVT后1年大截肢风险更高,但OS后无此差异。
  • MAPT组在EVT和OS后30天及1年的总生存率和无截肢生存率均低于DAPT组。

临床怎么用

  • 对于CLTI患者下肢血运重建后,出院时考虑使用DAPT可能改善生存和减少EVT后再干预。
  • DAPT未显示降低大截肢风险,临床决策需个体化权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The optimal antiplatelet regimen after lower extremity revascularization in patients with chronic limb-threatening ischemia (CLTI) is unknown because current recommendations are based on extrapolation of data from trials in coronary artery disease and stroke. METHODS: We identified all patients undergoing an elective lower extremity revascularization for CLTI in the Vascular Quality Initiative registry discharged on a mono antiplatelet agent (MAPT) or dual antiplatelet therapy (DAPT). RESULTS: From 2003 to 2018, 50,890 patients underwent revascularization procedures for CLTI, and were discharged on MAPT or DAPT. Of these, 33,781 patients underwent endovascular therapy (EVT), and 17,109 patients underwent open surgery (OS) procedures. The rate of major amputation at 30 days in the target limb in the EVT group was 0.3% and 0.4% in the OS group (P = .22). On Kaplan-Meier analyses, patients on MAPT at discharge had a higher risk of 1-year major amputation compared with DAPT after EVT but not after OS procedures. Patients on MAPT had lower overall survival and amputation-free survival at 30 days and 1 year compared with DAPT after both EVT and OS. At 1 year, the MAPT group was at higher risk for target lesion reintervention after EVT compared with the DAPT group (15.9% vs 13%; P = .0012). There was no significant difference in thrombosis at 1 year between the MAPT and DAPT groups either after EVT (3.9% vs 3.7%; P = .3048) or OS (3.1% vs 3.2%; P = .2893). On Cox regression analysis, DAPT was associated with improved survival but not major amputation after both EVT and OS. CONCLUSIONS: In patients with CLTI, DAPT at the time of discharge has a positive impact on amputation-free survival and overall survival after both EVT and OS as well as target lesion reintervention after EVT. DAPT was not associated with a positive impact on major amputation after either EVT or OS.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Ramanan B, Jeon-Slaughter H, Chen X, et al. Impact of dual antiplatelet therapy after lower extremity revascularization for chronic limb-threatening ischemia. J Vasc Surg. 2021. PMID: 34023428. doi:10.1016/j.jvs.2021.04.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。